Heterogeneous SARS-CoV-2 kinetics due to variable timing and intensity of immune responses.


Journal

medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986

Informations de publication

Date de publication:
29 Aug 2023
Historique:
pubmed: 4 9 2023
medline: 4 9 2023
entrez: 4 9 2023
Statut: epublish

Résumé

The viral kinetics of documented SARS-CoV-2 infections exhibit a high degree of inter-individual variability. We identified six distinct viral shedding patterns, which differed according to peak viral load, duration, expansion rate and clearance rate, by clustering data from 810 infections in the National Basketball Association cohort. Omicron variant infections in previously vaccinated individuals generally led to lower cumulative shedding levels of SARS-CoV-2 than other scenarios. We then developed a mechanistic mathematical model that recapitulated 1510 observed viral trajectories, including viral rebound and cases of reinfection. Lower peak viral loads were explained by a more rapid and sustained transition of susceptible cells to a refractory state during infection, as well as an earlier and more potent late, cytolytic immune response. Our results suggest that viral elimination occurs more rapidly during omicron infection, following vaccination, and following re-infection due to enhanced innate and acquired immune responses. Because viral load has been linked with COVID-19 severity and transmission risk, our model provides a framework for understanding the wide range of observed SARS-CoV-2 infection outcomes.

Identifiants

pubmed: 37662228
doi: 10.1101/2023.08.20.23294350
pmc: PMC10473815
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI121129
Pays : United States

Auteurs

Katherine Owens (K)

Fred Hutchinson Cancer Center, Vaccine and Infectious Diseases Division.

Shadisadat Esmaeili-Wellman (S)

Fred Hutchinson Cancer Center, Vaccine and Infectious Diseases Division.

Joshua T Schiffer (JT)

Fred Hutchinson Cancer Center, Vaccine and Infectious Diseases Division.
University of Washington, Department of Medicine.

Classifications MeSH